Combined treatment evidence

Combined treatment, usually meaning CBT plus an SSRI or SNRI, has been compared directly with each treatment alone in trials and meta-analyses. The general pattern is that combined treatment can offer an advantage over monotherapy in the short term, and the advantage tends to be clearer for more severe presentations. For milder anxiety, the added benefit of combining treatments is smaller, and either treatment alone is often sufficient.

The long-term picture is more nuanced. Once treatment ends, the gap between combined treatment and CBT alone narrows. Some evidence suggests CBT carries a relapse-protection advantage that medication alone doesn't, because the skills remain available to the patient after treatment stops. So combined treatment's short-term edge doesn't always translate into a lasting edge over CBT.

Sequencing also matters. Some patients respond well to medication first and add therapy once symptoms have eased enough to engage with it. Others can tolerate exposure-based CBT only after a partial medication response. The evidence doesn't identify one correct sequence for everyone.